[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361403-105":59,"doc-detail-361403-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-folate-receptors-for-the-detection-and-selective-treatment-of-cancer-advanced-precision-oncology-in-practice","Targeting Folate Receptors for the Detection and Selective Treatment of Cancer - Advanced Precision Oncology in Practice","","Precision oncology aims to discover novel, selective druggable targets that deliver strong anti-tumor effects while sparing healthy tissues. Tumor microenvironment and tumor immune microenvironment (TIME) shape progression and chemotherapy response, motivating immune-cell pathways as bona fide targets. Folate receptors FRα and FRβ, due to distinctive overexpression on specific malignancies and suppressor immune cells, enable noninvasive cancer detection, precise localization, and selective delivery of potent therapeutics. Recent FR-targeting strategies support guided resection, anti-cancer efficacy, and TIME reprogramming with minimal adverse effects, highlighted by AZD5335’s enhanced performance in low FRα-expressing tumors, including chemoresistant cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-folate-receptors-for-the-detection-and-selective-treatment-of-cancer-advanced-precision-oncology-in-practice/361403/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-folate-receptors-for-the-detection-and-selective-treatment-of-cancer-advanced-precision-oncology-in-practice/361403.png","ImageObject",300,407,{"name":92,"@type":93},"anakgang17","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are folate receptors FRα and FRβ considered optimal targets for precision oncology?","Question",{"text":112,"@type":113},"They show distinctive overexpression on the cell surface of specific human malignancies and suppressor immune cells, enabling noninvasive detection/localization and selective therapeutic payload delivery.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do tumor microenvironment and tumor immune microenvironment (TIME) influence cancer treatment response?",{"text":117,"@type":113},"Both modulate tumor progression and the response to chemotherapeutics, which supports targeting tumor-associated immune-cell pathways as druggable strategies.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the significance of AZD5335 in FRα-targeted therapy?",{"text":121,"@type":113},"AZD5335 is a clinically tested FRα-targeted antibody-drug conjugate carrying a topoisomerase I inhibitor payload and shows remarkable efficacy, including against low FRα-expressing tumors, with minimal side effects to healthy tissues.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361403,1790389289,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Ivyspring  \nInternational Publisher  \nInternationalJournal of Biological Sciences  \n2026; 22(13): 7018-7052. doi: 10.7150/ijbs.139733  \nReview  \nTargeting Folate Receptors for the Detection and Selective Treatment of Cancer: Advanced Precision Oncology in Practice  \nMichal Stark, Yehuda G. Assaraf􀀍  \nThe Fred Wyszkowski Cancer Research Laboratory, Faculty of Biology, The Technion-Israel Institute of Technology, Haifa 3200003, Israel.  \n􀀍 Corresponding author: Yehuda G. Assaraf: [assaraf@technion.ac.il](assaraf@technion.ac.il).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2026.06.23; Accepted: 2026.07.23; Published: 2026.07.30  \nAbstract  \nThe modern era of precision oncology strives to identify novel and selective druggable targets that, on the one hand, achieve efficacious anti-tumor activity, and on the other hand inflict minimal adverse effects to healthy tissues. The realization that both the tumor microenvironment and the tumor immune microenvironment (TIME) modulate tumor progression and response to chemotherapeutics, has pushed tumor-associated immune cells to the forefront as bona fide druggable targets. Based on their unique overexpression pattern on the cell surface of specific human malignancies and suppressor immune cells, folate receptors FRα and FRβ constitute optimal facilitators of noninvasive cancer detection and localization, as well as efficacious selective delivery of potent therapeutic payloads. Along this vein, this review highlights recent advanced strategies utilizing FR-targeting for precise tumor and metastatic lesion localization for guided surgical precision resection, potent anti-cancer efficacy and reprogramming of the suppressive TIME. Notably, these activities were accomplished with minimal side effects to healthy tissues. AZD5335, a recent clinically tested FRα-targeted antibody-drug conjugate carrying a topoisomerase I inhibitor payload, exceeded its predecessors by demonstrating remarkable efficacy against low FRα-expressing tumors as well. Thus, FRs emerge as selective and promising targets for advanced precision oncology of various malignancies including those displaying chemoresistance.  \nKeywords: folate receptor, cancer detection, selective targeting, tumor associated macrophages  \n1. Introduction  \nOne carbon metabolism, and specifically the folate cycle, provides one carbon units for the vital de novo biosynthesis of DNA (purine nucleotides and thymidylate) and amino acids (glycine and methionine), as well as for various cellular methylation reactions (DNA, RNA, histones, phospholipids and neurotransmitters) [1,2] . As such, folates (vitamin B9) are imperative for normal fetal development [3,4] and cellular health [5], however, they are also essential for carcinogenesis and cancer progression [6,7] . While folate cofactors are crucial for cellular functions, most eukaryotic cells lack the capability for de novo folate biosynthesis [1] . Hence, several transport routes mediate the uptake of folates into cells [8] . These include: 1) The predominant and  \nubiquitously expressed reduced folate carrier (RFC, SLC19A1) [9], 2) The principal intestinal folate absorption transporter, known as the proton-coupled folate transporter (PCFT, SLC46A1) [10], and 3) The glycosyl-phosphatidylinositol (GPI)-anchored membrane and soluble α, β and γ folate receptors (FRs)  \n[11] . Folic acid (FA) is a poor substrate of RFC (Km ~ 200 µM) which efficiently takes up the predominant blood circulating folate 5-methyltetrahydrofolate (5-MTHF) and other reduced folates with much higher affinity (Km ~ 1 µM) [12,13] . PCFT functions as a proton-driven folate influx transporter. As such, PCFT displays comparable Km values (~ 1.5 µM) for FA a","cbCaitlusAQNP6Lp","https://ap.wps.com/l/cbCaitlusAQNP6Lp","pdf",8082442,35,"English","# Introduction\n## One-carbon metabolism and the folate cycle\n## Folate transport routes and folate receptors\n## Biophysical binding properties and assay considerations\n## Tissue expression patterns and implications for targeted delivery","[{\"question\":\"Why are folate receptors FRα and FRβ considered optimal targets for precision oncology?\",\"answer\":\"They show distinctive overexpression on the cell surface of specific human malignancies and suppressor immune cells, enabling noninvasive detection/localization and selective therapeutic payload delivery.\"},{\"question\":\"How do tumor microenvironment and tumor immune microenvironment (TIME) influence cancer treatment response?\",\"answer\":\"Both modulate tumor progression and the response to chemotherapeutics, which supports targeting tumor-associated immune-cell pathways as druggable strategies.\"},{\"question\":\"What is the significance of AZD5335 in FRα-targeted therapy?\",\"answer\":\"AZD5335 is a clinically tested FRα-targeted antibody-drug conjugate carrying a topoisomerase I inhibitor payload and shows remarkable efficacy, including against low FRα-expressing tumors, with minimal side effects to healthy tissues.\"}]","Targeting Folate Receptors for the Detection and Selective Treatment of Cancer - Advanced Precision Oncology in Practice | PDF",1790144202,88,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a2800ea61928eaa0eb684bb4edc2157.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3745369dd953c2e3125ae898998fbe0.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b713e697665334bd41fa9577397ebb7.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35d7b7ab08e60ce53eb20a77947bff2f.webp",980,1268]